

## **Product datasheet for TL310183V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **Lubricin (PRG4) Human shRNA Lentiviral Particle (Locus ID 10216)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** Lubricin (PRG4) Human shRNA Lentiviral Particle (Locus ID 10216)

**Locus ID:** 10216

Synonyms: CACP; HAPO; JCAP; MSF; SZP Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** PRG4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001127708, NM 001127709, NM 001127710, NM 001303232, NM 005807,

NM 001127710.1, NM 001127710.2, NM 001127709.1, NM 001127709.2, NM 001127708.1,

NM 001127708.2, NM 001303232.1, NM 005807.2, NM 005807.3, NM 001303232.2

UniProt ID: Q92954

**Summary:** The protein encoded by this gene is a large proteoglycan that is synthesized by chondrocytes

located at the surface of articular cartilage and by some synovial lining cells. This protein contains both chondroitin sulfate and keratan sulfate glycosaminoglycans. It functions as a boundary lubricant at the cartilage surface and contributes to the elastic absorption and energy dissipation of synovial fluid. Mutations in this gene result in camptodactyly-arthropathy-coxa vara-pericarditis syndrome. Alternative splicing results in multiple

transcript variants. [provided by RefSeq, Dec 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



### Lubricin (PRG4) Human shRNA Lentiviral Particle (Locus ID 10216) - TL310183V

# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).